Lymph Node Ratio and Kras Mutation in R Colon Cancer

Colon Cancer Stage III Clinical Trial

Official title:

Lymph Node Ratio and Kras Mutation in Risk Stratification of Colon Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04342676
• Other study ID #: IRB 20202
• Status: Completed
• Phase: Phase 3
• Start date: March 10, 2017
• Est. completion date: August 26, 2019

Study information

• Verified date: April 2020
• Source: Mansoura University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

clinical impact of LN ratio with Kras expression in colon cancer

Description:

LNR and K ras were evaluated with correlated with different clinicopathological parameters of the patients, PFS and OS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 433
• Est. completion date: August 26, 2019
• Est. primary completion date: August 25, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 70 Years

Eligibility

Inclusion Criteria:

• Stage III colon cancer

Exclusion Criteria:

• Stage I, II, IV

Related Conditions & MeSH terms

• Colon Cancer Stage III
• Colonic Neoplasms

Intervention

Device:
• k ras
K ras

Drug:
• Panitumumab
vectibex in stage iv

Locations

Country	Name	City	State
Egypt	Mansoura University Oncology Center	Mansoura	Ad Daqahliyah

Sponsors (1)

Lead Sponsor	Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	LNR and K ras were evaluated with correlated with different clinicopathological parameters (Gender, CEA, tumor size, tumor grade and response to treatment).	impact on response	2 years
Secondary	LNR and K ras were evaluated and ASSOCIATION with PFS and OS.	impact on survival	2 years